Pain Treatments was Bioventus’s largest product and service line in fiscal 2025, bringing in $279.06M of $568.09M (49%).
| Product and Service | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Pain Treatments | $216.33M | $220.80M | $261.29M | $279.06M | |||
| Surgical Solutions | $148.28M | $161.60M | $189.26M | $203.65M | |||
| Restorative Therapies | $147.51M | $129.94M | $122.74M | $85.37M | |||
| Total | $512.12M | $512.35M | $573.28M | $568.09M |
Bioventus brought in $568.09M from its three product and service lines in fiscal 2025, the year ended December 31, 2025. That was down 0.9% from $573.28M in fiscal 2024. Pain Treatments was the largest at $279.06M (49.1%), ahead of Surgical Solutions at $203.65M (35.8%) and Restorative Therapies at $85.37M (15.0%).
Compared with fiscal 2024, Surgical Solutions grew fastest, up 7.6% to $203.65M, while Restorative Therapies fell the most, down 30.4% to $85.37M. From fiscal 2022 to 2025, combined revenue from these lines grew from $512.12M to $568.09M, a compound annual growth rate of 3.5%. Pain Treatments' share of the total rose from 42.2% to 49.1%.
U.S was Bioventus’s largest segment in fiscal 2025, bringing in $502.10M of $568.09M (88%).
| Segment | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| U.S | $455.25M | $449.86M | $506.81M | $502.10M |
| International | $56.87M | $62.49M | $66.47M | $65.99M |
| Total | $512.12M | $512.35M | $573.28M | $568.09M |
Bioventus brought in $568.09M from its two segments in fiscal 2025, the year ended December 31, 2025. That was down 0.9% from $573.28M in fiscal 2024. U.S was the largest at $502.10M (88.4%), ahead of International at $65.99M (11.6%).
Compared with fiscal 2024, International fell 0.7% to $65.99M and U.S fell 0.9% to $502.10M. From fiscal 2022 to 2025, combined revenue from these segments grew from $512.12M to $568.09M, a compound annual growth rate of 3.5%. U.S's share of the total fell from 88.9% to 88.4%.
U.S was Bioventus’s largest region in fiscal 2025, bringing in $502.10M of $568.09M (88%).
| Geography | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| U.S | $455.25M | $449.86M | $506.81M | $502.10M | |||
| International | $56.87M | $62.49M | $66.47M | $65.99M | |||
| Total | $512.12M | $512.35M | $573.28M | $568.09M |
Bioventus brought in $568.09M from its two regions in fiscal 2025, the year ended December 31, 2025. That was down 0.9% from $573.28M in fiscal 2024. U.S was the largest at $502.10M (88.4%), ahead of International at $65.99M (11.6%).
Compared with fiscal 2024, International fell 0.7% to $65.99M and U.S fell 0.9% to $502.10M. From fiscal 2022 to 2025, combined revenue from these regions grew from $512.12M to $568.09M, a compound annual growth rate of 3.5%. U.S's share of the total fell from 88.9% to 88.4%.
Bioventus (BVS) reports its revenue by product and service, by segment and by geography. In fiscal 2025, Pain Treatments was its largest product and service line, bringing in $279.06M (49.1% of the total), followed by Surgical Solutions at $203.65M (35.8%).
Pain Treatments was Bioventus' largest product and service line in fiscal 2025, bringing in $279.06M, or 49.1% of the $568.09M total across its three product and service lines.
U.S was Bioventus' largest segment in fiscal 2025, bringing in $502.10M, or 88.4% of the $568.09M total across its two segments.
U.S was Bioventus' largest region in fiscal 2025, bringing in $502.10M, or 88.4% of the $568.09M total across its two regions.
Among Bioventus' product and service lines that make up at least 2% of revenue, Surgical Solutions grew fastest in fiscal 2025, up 7.6% from $189.26M to $203.65M.
Every figure comes from Bioventus' annual financial filings, as reported. Each line keeps the name Bioventus gives it, and years follow its fiscal calendar.
Bioventus' revenue by product and service goes back to fiscal 2019, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.